Table II.
Association results assuming a multiplicative model.
| SNP | CHR | BP | Risk Allelea | Frequency in Cases | Frequency in Controls | Odds Ratio (95%CI)b | 2-sided P-Value | 1-sided P-Valuec |
|---|---|---|---|---|---|---|---|---|
| rs721048 (A/G) | 2p15 | 63,043,382 | A | 0.03 | 0.03 | 0.98 (0.40,2.18) | 0.96 | 0.52 |
| rs9364554 (C/T) | 6q25 | 160,804,075 | T | 0.07 | 0.06 | 1.11 (0.59,2.00) | 0.74 | 0.37 |
| rs10486567 (A/G) | 7p15 | 27,749,803 | G | 0.75 | 0.72 | 1.16 (0.83,1.64) | 0.38 | 0.19 |
| rs3747531 (C/G) | 8p22 | 16,057,019 | G | 0.05 | 0.07 | 0.69 (0.33,1.34) | 0.28 | 0.86 |
| rs1016343 (C/T) | 8q24 | 128,162,479 | T | 0.17 | 0.20 | 0.78 (0.52,1.16) | 0.22 | 0.89 |
| rs13254738 (A/C) | 8q24 | 128,173,525 | C | 0.68 | 0.63 | 1.24 (0.91,1.70) | 0.17 | 0.085 |
| rs6983561 (A/C)d | 8q24 | 128,176,062 | C | 0.56 | 0.45 | 1.55 (1.15,2.09) | 0.0039 | 0.0020 |
| rs16901979 (A/C) | 8q24 | 128,194,098 | A | 0.54 | 0.42 | 1.60 (1.17,2.19) | 0.0030 | 0.0015 |
| rs6983267 (G/T) | 8q24 | 128,482,487 | G | 0.93 | 0.88 | 1.64 (0.99,2.87) | 0.057 | 0.028 |
| rs7000448 (C/T) | 8q24 | 128,510,352 | T | 0.73 | 0.65 | 1.41 (1.03,1.94) | 0.030 | 0.015 |
| rs1447295 (A/C) | 8q24 | 128,554,220 | A | 0.32 | 0.31 | 1.03 (0.75,1.41) | 0.84 | 0.42 |
| rs4242382 (A/G) | 8q24 | 128,586,755 | A | 0.33 | 0.34 | 0.98 (0.73,1.31) | 0.90 | 0.55 |
| rs10090154 (C/T) | 8q24 | 128,601,319 | T | 0.18 | 0.17 | 1.04 (0.72,1.49) | 0.82 | 0.41 |
| rs10993994 (C/T) | 10q11 | 51,219,502 | T | 0.65 | 0.61 | 1.18 (0.87,1.60) | 0.29 | 0.15 |
| rs7904463 (C/T) | 10q11 | 51,229,475 | T | 0.72 | 0.64 | 1.42 (1.05,1.96) | 0.024 | 0.012 |
| rs10740051 (A/G) | 10q11 | 51,240,158 | A | 0.07 | 0.13 | 0.51 (0.29,0.85) | 0.0088 | 1.00 |
| rs4962416 (C/T) | 10q26 | 126,686,862 | C | 0.12 | 0.16 | 0.73 (0.47,1.12) | 0.16 | 0.92 |
| rs7931342 (G/T) | 11q13 | 68,751,073 | G | 0.80 | 0.80 | 1.01 (0.71,1.46) | 0.96 | 0.48 |
| rs10896449 (A/G) | 11q13 | 68,751,243 | G | 0.70 | 0.70 | 0.98 (0.73,1.34) | 0.90 | 0.55 |
| rs4430796 (A/G) | 17q12 | 33,172,153 | A | 0.35 | 0.35 | 1.03 (0.76,1.40) | 0.84 | 0.42 |
| rs7501939 (C/T) | 17q12 | 33,175,269 | C | 0.48 | 0.48 | 1.00 (0.75,1.33) | 0.99 | 0.50 |
| rs1859962 (G/T) | 17q24 | 66,620,348 | G | 0.29 | 0.31 | 0.92 (0.68,1.23) | 0.56 | 0.72 |
| rs2735839 (A/G) | 19q13 | 56,056,435 | G | 0.68 | 0.69 | 0.95 (0.70,1.31) | 0.77 | 0.62 |
| rs5945619 (C/T) | Xp11 | 51,074,708 | C | 0.41 | 0.38 | 1.08 (0.87,1.33) | 0.48 | 0.24 |
rs1447295 results reported previously in Amundadottir et al. [12]
a
As reported previously in European Americans or in Xu et al. [9]
b
Increased/decreased odds for each additional copy of risk allele.
c
1-sided test based on previously reported risk allele.
d
SNPs in bold were nominally associated with prostate cancer (P<0.05).